TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02149225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APVAC1 vaccine plus Poly-ICLC and GM-CSF
Description: APVAC1 vaccines (i.d.) will be individually assembled for each patient and can be applied to the patient approx. 3 months after enrollment. APVAC1 drug products are composed of 5 to 10 peptides from the GAPVAC warehouse. The APVAC1 vaccine will be applied concurrent to maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 15 of the first maintenance TMZ cycle, patients will receive 11 vaccinations with APVAC1 drug products during 22 weeks. 578 μg per peptide per vial are used.~Poly ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2\*) to avoid dose accumulation on consecutive days.~The 2. immunomodulator GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APVAC2 vaccine plus Poly-ICLC and GM-CSF
Description: APVAC2 vaccines (i.d.) will be ready for use ca. 6 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. APVAC2 drug products are composed of 1 or 2 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with APVAC2 drug products beginning on day 15 of the 4. maintenance TMZ cycle. Patients will receive 8 vaccinations within 10 weeks. 578 μg per peptide per vial are used.~Poly-ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2\*) to avoid dose accumulation on consecutive days.~GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs.
Study: NCT01172067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy
Description: Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimization using echocardiography
Description: Optimization of the AV/PV and VV delays using echocardiography
Study: NCT00624234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tutoring Program I
Description: Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tutoring Program I
Description: Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.
Study: NCT03005210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magicbuvir Plus
Description: 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Harvoni (fist dose)
Description: 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Harvoni (second dose)
Description: 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
Study: NCT02856360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Stiffness Footwear
Description: Standard moderately stiff footwear for typical high school football players will be randomly allocated to each group
Study: NCT00624234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tutoring Program II
Description: Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tutoring Program II
Description: Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.
Study: NCT05037604

Intervention type: DIAGNOSTIC_TEST
Intervention: Self questionnaire diagnostic tool
Description: Self questionnaire of physical characteristics

Intervention type: DIAGNOSTIC_TEST
Intervention: Self questionnaire diagnostic tool
Description: Self questionnaire of physical characteristics
Study: NCT05054855

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: : Cognitive Support Technology (CST)
Description: Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment.~CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: : Cognitive Support Technology (CST)
Description: Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment.~CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012).
Study: NCT01361256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telescope prosthesis
Description: Monocular implantation of the telescope prosthesis after cataract extraction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WA-NG Telescope Prothesis
Description: The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
Study: NCT03069911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA (29 units for women; 40 units for men) diluted with 0.9% sodium chloride (saline) solution to 40 units per milliliter (mL) (0.725 mL for women, 1 mL for men)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 0.9% sodium chloride solution (saline) solution injections (0.725mL for women, 1mL for men)
Study: NCT02836561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone message
Description: A pre-visit telephone intervention describing availability of long-acting reversible contraceptives at time of uterine evacuation
Study: NCT00944827

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Tea Extract - Catechins
Description: Combination treatment with 20 mg atorvastatin and 600mg green tea extract, daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination treatment with 20 mg atorvastatin and 600mg placebo, daily for 12 weeks
Study: NCT00817271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: 1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8
Study: NCT04957563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: olfactory rehabilitation
Description: treatment for improve olfactory function
Study: NCT04265664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Participants in the telerehabilitation program will receive a graded exercise and self-management intervention. This program will be delivered in a ≤2:1 participant:therapist ratio. Each participant grouping will receive two 60-90 minutes telerehabilitation sessions per week for 4 weeks focusing on lower extremity recovery (total 8-12 hours), with a therapist trained in the use of technology for the provision of rehabilitation. Participants will also be asked to complete at least one additional independent self-managed exercise session each week. This independent exercise session will include selected exercises from the telerehabilitation sessions that will be safe to perform without therapist oversight, and jointly agreed upon by the participant and therapist.
Study: NCT06353672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic liver resection
Description: Liver resection using Da Vinci robotic system
Study: NCT01724892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol etabonate
Study: NCT00682656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucantime®
Description: 15mg Sb+5/Kg/day, during 20 days. Maximum dose:15ml/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zithromax ®
Description: Zithromax ®/ Pfizer, 500 mg - 1x day, during 20 days
Study: NCT01993472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andrographolides
Description: comparison of efficacy of Andrographolides combined with Capecitabine or Capecitabine alone in treatment of colorectal cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study: NCT01956006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone
Description: Administration of study medications, PK sampling and safety profile- add on haemodynamic invasive measurements if patient consents to.
Study: NCT02792140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: one week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one week
Study: NCT03758586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computerized spatial skill training
Description: The spatial skills training session consisted of six practice trials that were run in a sequence. The objective of each practice was to manipulate the simulated robotic arm to grab the cubes and move them to a desired location using keyboard keys. The participant was required to reach a decision based on the visual-spatial information, before initiating subsequent movements of the simulated robotic arm. Each practice trial presented an initial state of the cubes in front of the robotic arm, and a target position of the cubes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Watching a presentation regarding robotic surgery
Description: Watching a 20-35 minute long power-point presentation regarding the history of robotic surgery.
Study: NCT03955367

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic extended-field Irradiation
Description: CTV covers pelvis and para-aortic lymph nodes region.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic irradiation
Description: CTV covers pelvis.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intracavitary brachytherapy
Description: The total dose delivered to point A or high-risk CTV is ≥80Gy. For patients with larger-volume cervical tumor, the total dose is ≥85Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intracavitary brachytherapy
Description: The total dose delivered to point A or high-risk CTV is ≥80Gy. For patients with larger-volume cervical tumor, the total dose is ≥85Gy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemotherapy
Description: Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.
Study: NCT02856360

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Stiffness Footwear
Description: Standard highly stiff footwear for typical high school football players will be randomly allocated to each group
Study: NCT02878057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
Study: NCT03955367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.
Study: NCT03377647

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Care Provider Training
Description: In this intervention, asthma care providers will be trained in current, evidence-based guidelines for care of children with asthma, and will be provided with tools that their practice may use to facilitate care improvements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Care Provider Training
Description: In this intervention, asthma care providers will be trained in current, evidence-based guidelines for care of children with asthma, and will be provided with tools that their practice may use to facilitate care improvements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Care Provider Training
Description: In this intervention, asthma care providers will be trained in current, evidence-based guidelines for care of children with asthma, and will be provided with tools that their practice may use to facilitate care improvements.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School Staff Asthma Education
Description: In this intervention, teachers and other school staff will be provided current, evidence-based training in understanding asthma and will be provided tools to help schools address the special needs of children with asthma.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School Staff Asthma Education
Description: In this intervention, teachers and other school staff will be provided current, evidence-based training in understanding asthma and will be provided tools to help schools address the special needs of children with asthma.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School Staff Asthma Education
Description: In this intervention, teachers and other school staff will be provided current, evidence-based training in understanding asthma and will be provided tools to help schools address the special needs of children with asthma.
Study: NCT00885079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-12759 Ophthalmic suspension
Description: OPC-12759 Ophthalmic suspension 2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyalein Mini Ophthalmic solution
Description: Hyalein Mini Ophthalmic solution 0.1%
Study: NCT01593007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: All participants were instructed to use a Threshold® trainer for 30min a day, seven times a week over 12 consecutive weeks.10 Patients in the Control Group used a Threshold ® device without resistance, making them blind to the treatment. For the treatment group, inspiratory resistance of the Threshold® trainer was 30% of MIP, adjusted on a weekly basis to remain constant.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
Study: NCT01376167

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine 600mg
Description: 600mg Chloroquine given to each subject on Day 1 and Day2 of the trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine 600mg
Description: 600mg Chloroquine given to each subject on Day 1 and Day2 of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine 600mg
Description: 600mg Chloroquine given to each subject on Day 1 and Day2 of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine 600mg
Description: 600mg Chloroquine given to each subject on Day 1 and Day2 of the trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine 600mg
Description: 600mg Chloroquine given to each subject on Day 1 and Day2 of the trial
Study: NCT02404987

Intervention type: OTHER
Intervention: Nutritional Supplement
Study: NCT02548702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit4Life
Description: Fit4Life is a programme whereby patients with type 2 diabetes are counselled and then allocated to a community-based sport programme based on their interests and perceived barriers to participation
Study: NCT01376167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine 600mg
Description: 600mg Chloroquine given to each subject on Day 1 and Day2 of the trial
Study: NCT00623571

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of elderly patients in a GMW
Study: NCT01376167

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine 300mg
Description: 300mg Chloroquine given to each subject on Day 3 of the trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine 300mg
Description: 300mg Chloroquine given to each subject on Day 3 of the trial
Study: NCT00623571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of elderly patients in GHHS
Study: NCT00815958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)
Description: During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the RIA group (Arm A), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines up until femoral reaming. These patients will receive reaming with RIA. The remainder of the surgery will also be done according to the standard of care. TEE and TCD data will be recorded throughout the surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reaming with conventional reamer
Description: During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the control group (Arm B), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines. These patients will receive reaming with the conventional method/reamer. TEE and TCD data will be recorded throughout the surgery.
Study: NCT01743573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga
Study: NCT02643095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scleral contact lens
Description: Scleral contact lens